Clinical Trials

CUP (carcinoma of unknown primary syndrome)

Recruitment stopped
Ongoing Recruitment

NCT-PMO-1603 TOP-ART

(second-line, BRCAness)
Title:A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Indication:Krebs mit DNA-Reparatur-Defizite
Type of study:Phase II
Contact: Barbara Stöhr (Study Nurse)
[barbara.stoehr@nct-heidelberg.de]
Investigator: Prof. Dr. Stefan Fröhling (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03127215
EudraCT: 2017-001755-31 (siehe EU klinisches Studienregister)

CUPISCO/MX39795

Title:A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
Indication:CUP (Krebserkrankung ohne Primärtumor)
Type of study:Phase II
Contact: Marie-Christin Vollmer (Study Nurse)
[Marie-Christin.Vollmer@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Alwin Krämer (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03498521
EudraCT: 2017-003040-20 (siehe EU klinisches Studienregister)